ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

PRALUENT
Hyperlipoproteinemias
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

PRALUENT Rx

Generic Name and Formulations:
Alirocumab 75mg/mL, 150mg/mL; soln for SC inj; preservative-free.

Company:
Sanofi US and Regeneron

Therapeutic Use:

Indications for PRALUENT:

Adjunct to diet and maximally tolerated statin therapy, in adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease requiring additional lowering of LDL-C.

Limitations Of use:

Effect on cardiovascular morbidity and mortality has not been determined.

Adult:

Give by SC inj into thigh, abdomen, or upper arm; rotate inj sites. Initially 75mg once every 2 weeks. Measure LDL-C levels within 4–8 weeks of initiation or titration; may increase to max 150mg given every 2 weeks if LDL-C response is inadequate. Alternative monthly regimen: initially 300mg (two 150mg injs consecutively at two different sites) once every 4 weeks. Measure LDL-C levels just prior to next scheduled dose; may adjust dose to 150mg every 2 weeks, starting on next scheduled dosing date if LDL-C response is inadequate.

Children:

Not established.

Warnings/Precautions:

Do not inject into areas of active skin disease or injury (eg, sunburns, rashes, inflammation, skin infections). Discontinue if serious allergic reactions occur. Pregnancy (2nd & 3rd trimesters). Nursing mothers.

Interactions:

Avoid co-administration with other injectable drugs at same inj site.

Pharmacological Class:

Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor.

Adverse Reactions:

Nasopharyngitis, inj site reactions (eg, erythema/redness, itching, swelling, pain/tenderness), influenza.

Generic Availability:

NO

How Supplied:

Single-dose prefilled pen or syringe (1mL)—1, 2

Sign Up for Free e-Newsletters